脆性 X 综合征患者使用米诺环素治疗的副作用及疗效评估方法的探索。
Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.
机构信息
M.I.N.D. Institute, University of California at Davis Medical Center, USA.
出版信息
Am J Intellect Dev Disabil. 2010 Sep;115(5):433-43. doi: 10.1352/1944-7558-115.5.433.
Abstract
Minocycline can rescue the dendritic spine and synaptic structural abnormalities in the fragile X knock-out mouse. This is a review and preliminary survey to document side effects and potential outcome measures for minocycline use in the treatment of individuals with fragile X syndrome. We surveyed 50 patients with fragile X syndrome who received minocycline for at least 2 weeks and found that the most common reported side effect is gastrointestinal difficulty, including loss of appetite. The families reported an improvement in language and behavioral areas. Outcome measures in the design of future randomized clinical trials should include both behavioral and language measures. As with any other treatments, we emphasize that randomized clinical trials are needed to determine the efficacy of minocycline in fragile X syndrome.
摘要
米诺环素可挽救脆性 X 敲除小鼠的树突棘和突触结构异常。本文旨在综述并初步调查米诺环素治疗脆性 X 综合征患者的副作用和潜在的结果评估方法。我们调查了 50 名接受米诺环素治疗至少 2 周的脆性 X 综合征患者，发现最常见的报告副作用是胃肠道困难，包括食欲不振。家庭报告语言和行为方面有所改善。未来随机临床试验的设计中应包括行为和语言评估方法。与任何其他治疗方法一样，我们强调需要进行随机临床试验以确定米诺环素治疗脆性 X 综合征的疗效。
相似文献
1
Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.
Am J Intellect Dev Disabil. 2010 Sep;115(5):433-43. doi: 10.1352/1944-7558-115.5.433.
2
A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.
J Dev Behav Pediatr. 2013 Apr;34(3):147-55. doi: 10.1097/DBP.0b013e318287cd17.
3
High MMP-9 activity levels in fragile X syndrome are lowered by minocycline.
Am J Med Genet A. 2013 Aug;161A(8):1897-903. doi: 10.1002/ajmg.a.36023. Epub 2013 Jul 3.
4
Electrocortical changes associated with minocycline treatment in fragile X syndrome.
J Psychopharmacol. 2013 Oct;27(10):956-63. doi: 10.1177/0269881113494105. Epub 2013 Aug 27.
5
Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
J Med Genet. 2009 Feb;46(2):94-102. doi: 10.1136/jmg.2008.061796. Epub 2008 Oct 3.
6
Open-label add-on treatment trial of minocycline in fragile X syndrome.
BMC Neurol. 2010 Oct 11;10:91. doi: 10.1186/1471-2377-10-91.
7
Revisiting safety of minocycline as neuroprotection in Huntington's disease.
Mov Disord. 2007 Jan 15;22(2):292. doi: 10.1002/mds.21199.
8
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment.
J Psychopharmacol. 2012 Sep;26(9):1185-93. doi: 10.1177/0269881112444941. Epub 2012 Apr 23.
9
Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne.
Health Technol Assess. 2005 Jan;9(1):iii-212. doi: 10.3310/hta9010.
10
A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study).
Orphanet J Rare Dis. 2018 Aug 20;13(1):144. doi: 10.1186/s13023-018-0891-6.
引用本文的文献
1
Astrocytes in fragile X syndrome.
Front Cell Neurosci. 2024 Jan 8;17:1322541. doi: 10.3389/fncel.2023.1322541. eCollection 2023.
2
Enhanced Targeted Delivery of Minocycline via Transferrin Conjugated Albumin Nanoparticle Improves Neuroprotection in a Blast Traumatic Brain Injury Model.
Brain Sci. 2023 Feb 25;13(3):402. doi: 10.3390/brainsci13030402.
3
Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome.
Sci Rep. 2022 Sep 13;12(1):15386. doi: 10.1038/s41598-022-19476-y.
4
Targeted therapy of cognitive deficits in fragile X syndrome.
Mol Psychiatry. 2022 Jun;27(6):2766-2776. doi: 10.1038/s41380-022-01527-5. Epub 2022 Mar 30.
5
EEG as a translational biomarker and outcome measure in fragile X syndrome.
Transl Psychiatry. 2022 Jan 24;12(1):34. doi: 10.1038/s41398-022-01796-2.
6
The Use of Peptides in the Treatment of Fragile X Syndrome: Challenges and Opportunities.
Front Psychiatry. 2021 Nov 4;12:754485. doi: 10.3389/fpsyt.2021.754485. eCollection 2021.
7
A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders.
Int J Neuropsychopharmacol. 2021 Sep 21;24(9):734-748. doi: 10.1093/ijnp/pyab036.
8
Rapamycin, but not minocycline, significantly alters ultrasonic vocalization behavior in C57BL/6J pups in a flurothyl seizure model.
Behav Brain Res. 2021 Jul 23;410:113317. doi: 10.1016/j.bbr.2021.113317. Epub 2021 Apr 25.
9
Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome.
Brain Sci. 2020 Jun 10;10(6):361. doi: 10.3390/brainsci10060361.
10
Phytochemicals against TNFα-Mediated Neuroinflammatory Diseases.
Int J Mol Sci. 2020 Jan 24;21(3):764. doi: 10.3390/ijms21030764.
本文引用的文献
1
Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population.
J Mol Diagn. 2009 Jul;11(4):324-9. doi: 10.2353/jmoldx.2009.080173. Epub 2009 May 21.
2
Brief report: Visual processing of faces in individuals with fragile X syndrome: an eye tracking study.
J Autism Dev Disord. 2009 Jun;39(6):946-52. doi: 10.1007/s10803-009-0744-1. Epub 2009 Apr 28.
3
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.
J Med Genet. 2009 Apr;46(4):266-71. doi: 10.1136/jmg.2008.063701. Epub 2009 Jan 6.
4
Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS).
Brain Res. 2009 Feb 9;1253:176-83. doi: 10.1016/j.brainres.2008.11.075. Epub 2008 Dec 3.
5
Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease.
FASEB J. 2009 Mar;23(3):739-50. doi: 10.1096/fj.08-113795. Epub 2008 Nov 11.
6
Minocycline and neurodegenerative diseases.
Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11.
7
Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function.
Neuron. 2008 Oct 23;60(2):201-14. doi: 10.1016/j.neuron.2008.10.004.
8
Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors.
Neurosci Lett. 2008 Dec 12;447(2-3):134-7. doi: 10.1016/j.neulet.2008.10.006. Epub 2008 Oct 7.
9
Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency.
Neuropsychopharmacology. 2009 Mar;34(4):1011-26. doi: 10.1038/npp.2008.152. Epub 2008 Oct 8.
10
Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
J Med Genet. 2009 Feb;46(2):94-102. doi: 10.1136/jmg.2008.061796. Epub 2008 Oct 3.
Zotero 插件